1
|
Midroni J, Salunkhe R, Liu Z, Chow R, Boldt G, Palma D, Hoover D, Vinogradskiy Y, Raman S. Incorporation of Functional Lung Imaging Into Radiation Therapy Planning in Patients With Lung Cancer: A Systematic Review and Meta-Analysis. Int J Radiat Oncol Biol Phys 2024; 120:370-408. [PMID: 38631538 PMCID: PMC11580018 DOI: 10.1016/j.ijrobp.2024.04.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Revised: 03/27/2024] [Accepted: 04/02/2024] [Indexed: 04/19/2024]
Abstract
Our purpose was to provide an understanding of current functional lung imaging (FLI) techniques and their potential to improve dosimetry and outcomes for patients with lung cancer receiving radiation therapy (RT). Excerpta Medica dataBASE (EMBASE), PubMed, and Cochrane Library were searched from 1990 until April 2023. Articles were included if they reported on FLI in one of: techniques, incorporation into RT planning for lung cancer, or quantification of RT-related outcomes for patients with lung cancer. Studies involving all RT modalities, including stereotactic body RT and particle therapy, were included. Meta-analyses were conducted to investigate differences in dose-function parameters between anatomic and functional RT planning techniques, as well as to investigate correlations of dose-function parameters with grade 2+ radiation pneumonitis (RP). One hundred seventy-eight studies were included in the narrative synthesis. We report on FLI modalities, dose-response quantification, functional lung (FL) definitions, FL avoidance techniques, and correlations between FL irradiation and toxicity. Meta-analysis results show that FL avoidance planning gives statistically significant absolute reductions of 3.22% to the fraction of well-ventilated lung receiving 20 Gy or more, 3.52% to the fraction of well-perfused lung receiving 20 Gy or more, 1.3 Gy to the mean dose to the well-ventilated lung, and 2.41 Gy to the mean dose to the well-perfused lung. Increases in the threshold value for defining FL are associated with decreases in functional parameters. For intensity modulated RT and volumetric modulated arc therapy, avoidance planning results in a 13% rate of grade 2+ RP, which is reduced compared with results from conventional planning cohorts. A trend of increased predictive ability for grade 2+ RP was seen in models using FL information but was not statistically significant. FLI shows promise as a method to spare FL during thoracic RT, but interventional trials related to FL avoidance planning are sparse. Such trials are critical to understanding the effect of FL avoidance planning on toxicity reduction and patient outcomes.
Collapse
Affiliation(s)
- Julie Midroni
- Temerty Faculty of Medicine, University of Toronto, Toronto, Canada; Radiation Medicine Program, Princess Margaret Cancer Center, Toronto, Canada
| | - Rohan Salunkhe
- Radiation Medicine Program, Princess Margaret Cancer Center, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Canada
| | - Zhihui Liu
- Biostatistics, Princess Margaret Cancer Center, Toronto, Canada
| | - Ronald Chow
- Temerty Faculty of Medicine, University of Toronto, Toronto, Canada; Radiation Medicine Program, Princess Margaret Cancer Center, Toronto, Canada; London Regional Cancer Program, London Health Sciences Centre, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
| | - Gabriel Boldt
- London Regional Cancer Program, London Health Sciences Centre, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
| | - David Palma
- London Regional Cancer Program, London Health Sciences Centre, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada; Ontario Institute for Cancer Research, Toronto, Canada
| | - Douglas Hoover
- London Regional Cancer Program, London Health Sciences Centre, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
| | - Yevgeniy Vinogradskiy
- Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, United States of America; Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, United States of America
| | - Srinivas Raman
- Radiation Medicine Program, Princess Margaret Cancer Center, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Canada.
| |
Collapse
|
7
|
Liu Z, Miao J, Huang P, Wang W, Wang X, Zhai Y, Wang J, Zhou Z, Bi N, Tian Y, Dai J. A deep learning method for producing ventilation images from 4DCT: First comparison with technegas SPECT ventilation. Med Phys 2020; 47:1249-1257. [PMID: 31883382 DOI: 10.1002/mp.14004] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2019] [Revised: 12/13/2019] [Accepted: 12/23/2019] [Indexed: 01/19/2023] Open
Abstract
PURPOSE The purpose of this study is to develop a deep learning (DL) method for producing four-dimensional computed tomography (4DCT) ventilation imaging and to evaluate the accuracy of the DL-based ventilation imaging against single-photon emission-computed tomography (SPECT) ventilation imaging (SPECT-VI). The performance of the DL-based method is assessed by comparing with density change- and Jacobian-based (HU and JAC) methods. MATERIALS AND METHODS Fifty patients with esophagus or lung cancer who underwent thoracic radiotherapy were enrolled in this study. For each patient, 4DCT scans paired with 99mTc-Technegas SPECT/CT were acquired before the first radiotherapy treatment. 4DCT and SPECT/CT were first rigidly registered using MIMvista and converted to data matrix using MATLAB, and then transferred to a DL model based on U-net for correlating 4DCT features and SPECT-VI. Two forms of 4DCT dataset [(a) ten phases and (b) two phases of peak-exhalation and peak-inhalation] as input are studied. Tenfold cross-validation procedure was used to evaluate the performance of the DL model. For comparative evaluation, HU and JAC methodologies are used to calculate specific ventilation imaging based on 4DCT (CTVI) for each patient. The voxel-wise Spearman's correlation was evaluated over the whole lung between each of CTVI and corresponding SPECT-VI. The SPECT-VI and produced CTVIs were segmented into high, median, and low functional lung (HFL, MFL, and LFL) regions. The spatial overlap of corresponding HFL, MFL, and LFL for each CTVI against SPECT-VI was also evaluated using the dice similarity coefficient (DSC). The averaged DSC of functional lung regions was calculated and statistically analyzed with a one-factor ANONA model among different methods. RESULTS The voxel-wise Spearman rs values were (0.22 ± 0.31), (-0.09 ± 0.18), and (0.73 ± 0.16)/(0.71 ± 0.17) for the CTVIHU , CTVIJAC , and CTVIDL(1) /CTVIDL(2) . These results showed the DL method yielded the strongest correlation with SPECT-VI. Using the DSC as the spatial overlap metric, we found that the CTVIHU , CTVIJAC , and CTVIDL(1) /CTVIDL(2) methods achieved averaged DSC values for all patients to be (0.45 ± 0.08), (0.33 ± 0.04), and (0.73 ± 0.09)/(0.71 ± 0.09), respectively. The results demonstrated that the DL method yielded the highest similarity with SPECT-VI with the prominently significant difference (P < 10-7 ). CONCLUSIONS This study developed a DL method for producing CTVI and performed a validation against SPECT-VI. The results demonstrated that DL method can derive CTVI with greatly improved accuracy in comparison to HU and JAC methods. The produced ventilation images can be more accurate and useful for lung functional avoidance radiotherapy and treatment response modeling.
Collapse
Affiliation(s)
- Zhiqiang Liu
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuannanli, Chaoyang District, Beijing, 100021, China
| | - Junjie Miao
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuannanli, Chaoyang District, Beijing, 100021, China
| | - Peng Huang
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuannanli, Chaoyang District, Beijing, 100021, China
| | - Wenqing Wang
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuannanli, Chaoyang District, Beijing, 100021, China
| | - Xin Wang
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuannanli, Chaoyang District, Beijing, 100021, China
| | - Yirui Zhai
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuannanli, Chaoyang District, Beijing, 100021, China
| | - Jingbo Wang
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuannanli, Chaoyang District, Beijing, 100021, China
| | - Zongmei Zhou
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuannanli, Chaoyang District, Beijing, 100021, China
| | - Nan Bi
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuannanli, Chaoyang District, Beijing, 100021, China
| | - Yuan Tian
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuannanli, Chaoyang District, Beijing, 100021, China
| | - Jianrong Dai
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuannanli, Chaoyang District, Beijing, 100021, China
| |
Collapse
|
13
|
Tahir BA, Van Holsbeke C, Ireland RH, Swift AJ, Horn FC, Marshall H, Kenworthy JC, Parra-Robles J, Hartley R, Kay R, Brightling CE, De Backer J, Vos W, Wild JM. Comparison of CT-based Lobar Ventilation with 3He MR Imaging Ventilation Measurements. Radiology 2015; 278:585-92. [PMID: 26322908 DOI: 10.1148/radiol.2015142278] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
PURPOSE To compare lobar lung ventilation computed from expiratory and inspiratory computed tomographic (CT) data with direct measurements of ventilation at hyperpolarized helium 3 ((3)He) magnetic resonance (MR) imaging by using same-breath hydrogen 1 ((1)H) MR imaging examinations to coregister the multimodality images. MATERIALS AND METHODS The study was approved by the national research ethics committee, and written patient consent was obtained. Thirty patients with asthma underwent breath-hold CT at total lung capacity and functional residual capacity. (3)He and (1)H MR images were acquired during the same breath hold at a lung volume of functional residual capacity plus 1 L. Lobar segmentations delineated by major fissures on both CT scans were used to calculate the percentage of ventilation per lobe from the change in inspiratory and expiratory lobar volumes. CT-based ventilation was compared with (3)He MR imaging ventilation by using diffeomorphic image registration of (1)H MR imaging to CT, which enabled indirect registration of (3)He MR imaging to CT. Statistical analysis was performed by using the Wilcoxon signed-rank test, Pearson correlation coefficient, and Bland-Altman analysis. RESULTS The mean ± standard deviation absolute difference between the CT and (3)He MR imaging percentage of ventilation volume in all lobes was 4.0% (right upper and right middle lobes, 5.4% ± 3.3; right lower lobe, 3.7% ± 3.9; left upper lobe, 2.8% ± 2.7; left lower lobe, 3.9% ± 2.6; Wilcoxon signed-rank test, P < .05). The Pearson correlation coefficient between the two techniques in all lobes was 0.65 (P < .001). Greater percentage of ventilation was seen in the upper lobes with (3)He MR imaging and in the lower lobes with CT. This was confirmed with Bland-Altman analysis, with 95% limits of agreement for right upper and middle lobes, -2.4, 12.7; right lower lobe, -11.7, 4.6; left upper lobe, -4.9, 8.7; and left lower lobe, -9.8, 2.8. CONCLUSION The percentage of regional ventilation per lobe calculated at CT was comparable to a direct measurement of lung ventilation at hyperpolarized (3)He MR imaging. This work provides evidence for the validity of the CT model, and same-breath (1)H MR imaging enables regional interpretation of (3)He ventilation MR imaging on the underlying lung anatomy at thin-section CT.
Collapse
Affiliation(s)
- Bilal A Tahir
- From the Academic Units of Academic Radiology (B.A.T., A.J.S., F.C.H., H.M., J.C.K., J.P.R., J.M.W.) and Clinical Oncology (B.A.T., R.H.I.), University of Sheffield, C Floor, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, England; Fluidda, Kontich, Belgium (C.V.H., J.D.B., W.V.); Institute for Lung Health, University of Leicester, Leicester, England (R.H., C.E.B.); Novartis, Basel, Switzerland (R.K.); and INSIGNEO Institute of In-silico Medicine, Sheffield, England (A.J.S., J.M.W.)
| | - Cedric Van Holsbeke
- From the Academic Units of Academic Radiology (B.A.T., A.J.S., F.C.H., H.M., J.C.K., J.P.R., J.M.W.) and Clinical Oncology (B.A.T., R.H.I.), University of Sheffield, C Floor, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, England; Fluidda, Kontich, Belgium (C.V.H., J.D.B., W.V.); Institute for Lung Health, University of Leicester, Leicester, England (R.H., C.E.B.); Novartis, Basel, Switzerland (R.K.); and INSIGNEO Institute of In-silico Medicine, Sheffield, England (A.J.S., J.M.W.)
| | - Rob H Ireland
- From the Academic Units of Academic Radiology (B.A.T., A.J.S., F.C.H., H.M., J.C.K., J.P.R., J.M.W.) and Clinical Oncology (B.A.T., R.H.I.), University of Sheffield, C Floor, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, England; Fluidda, Kontich, Belgium (C.V.H., J.D.B., W.V.); Institute for Lung Health, University of Leicester, Leicester, England (R.H., C.E.B.); Novartis, Basel, Switzerland (R.K.); and INSIGNEO Institute of In-silico Medicine, Sheffield, England (A.J.S., J.M.W.)
| | - Andrew J Swift
- From the Academic Units of Academic Radiology (B.A.T., A.J.S., F.C.H., H.M., J.C.K., J.P.R., J.M.W.) and Clinical Oncology (B.A.T., R.H.I.), University of Sheffield, C Floor, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, England; Fluidda, Kontich, Belgium (C.V.H., J.D.B., W.V.); Institute for Lung Health, University of Leicester, Leicester, England (R.H., C.E.B.); Novartis, Basel, Switzerland (R.K.); and INSIGNEO Institute of In-silico Medicine, Sheffield, England (A.J.S., J.M.W.)
| | - Felix C Horn
- From the Academic Units of Academic Radiology (B.A.T., A.J.S., F.C.H., H.M., J.C.K., J.P.R., J.M.W.) and Clinical Oncology (B.A.T., R.H.I.), University of Sheffield, C Floor, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, England; Fluidda, Kontich, Belgium (C.V.H., J.D.B., W.V.); Institute for Lung Health, University of Leicester, Leicester, England (R.H., C.E.B.); Novartis, Basel, Switzerland (R.K.); and INSIGNEO Institute of In-silico Medicine, Sheffield, England (A.J.S., J.M.W.)
| | - Helen Marshall
- From the Academic Units of Academic Radiology (B.A.T., A.J.S., F.C.H., H.M., J.C.K., J.P.R., J.M.W.) and Clinical Oncology (B.A.T., R.H.I.), University of Sheffield, C Floor, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, England; Fluidda, Kontich, Belgium (C.V.H., J.D.B., W.V.); Institute for Lung Health, University of Leicester, Leicester, England (R.H., C.E.B.); Novartis, Basel, Switzerland (R.K.); and INSIGNEO Institute of In-silico Medicine, Sheffield, England (A.J.S., J.M.W.)
| | - John C Kenworthy
- From the Academic Units of Academic Radiology (B.A.T., A.J.S., F.C.H., H.M., J.C.K., J.P.R., J.M.W.) and Clinical Oncology (B.A.T., R.H.I.), University of Sheffield, C Floor, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, England; Fluidda, Kontich, Belgium (C.V.H., J.D.B., W.V.); Institute for Lung Health, University of Leicester, Leicester, England (R.H., C.E.B.); Novartis, Basel, Switzerland (R.K.); and INSIGNEO Institute of In-silico Medicine, Sheffield, England (A.J.S., J.M.W.)
| | - Juan Parra-Robles
- From the Academic Units of Academic Radiology (B.A.T., A.J.S., F.C.H., H.M., J.C.K., J.P.R., J.M.W.) and Clinical Oncology (B.A.T., R.H.I.), University of Sheffield, C Floor, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, England; Fluidda, Kontich, Belgium (C.V.H., J.D.B., W.V.); Institute for Lung Health, University of Leicester, Leicester, England (R.H., C.E.B.); Novartis, Basel, Switzerland (R.K.); and INSIGNEO Institute of In-silico Medicine, Sheffield, England (A.J.S., J.M.W.)
| | - Ruth Hartley
- From the Academic Units of Academic Radiology (B.A.T., A.J.S., F.C.H., H.M., J.C.K., J.P.R., J.M.W.) and Clinical Oncology (B.A.T., R.H.I.), University of Sheffield, C Floor, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, England; Fluidda, Kontich, Belgium (C.V.H., J.D.B., W.V.); Institute for Lung Health, University of Leicester, Leicester, England (R.H., C.E.B.); Novartis, Basel, Switzerland (R.K.); and INSIGNEO Institute of In-silico Medicine, Sheffield, England (A.J.S., J.M.W.)
| | - Richard Kay
- From the Academic Units of Academic Radiology (B.A.T., A.J.S., F.C.H., H.M., J.C.K., J.P.R., J.M.W.) and Clinical Oncology (B.A.T., R.H.I.), University of Sheffield, C Floor, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, England; Fluidda, Kontich, Belgium (C.V.H., J.D.B., W.V.); Institute for Lung Health, University of Leicester, Leicester, England (R.H., C.E.B.); Novartis, Basel, Switzerland (R.K.); and INSIGNEO Institute of In-silico Medicine, Sheffield, England (A.J.S., J.M.W.)
| | - Chris E Brightling
- From the Academic Units of Academic Radiology (B.A.T., A.J.S., F.C.H., H.M., J.C.K., J.P.R., J.M.W.) and Clinical Oncology (B.A.T., R.H.I.), University of Sheffield, C Floor, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, England; Fluidda, Kontich, Belgium (C.V.H., J.D.B., W.V.); Institute for Lung Health, University of Leicester, Leicester, England (R.H., C.E.B.); Novartis, Basel, Switzerland (R.K.); and INSIGNEO Institute of In-silico Medicine, Sheffield, England (A.J.S., J.M.W.)
| | - Jan De Backer
- From the Academic Units of Academic Radiology (B.A.T., A.J.S., F.C.H., H.M., J.C.K., J.P.R., J.M.W.) and Clinical Oncology (B.A.T., R.H.I.), University of Sheffield, C Floor, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, England; Fluidda, Kontich, Belgium (C.V.H., J.D.B., W.V.); Institute for Lung Health, University of Leicester, Leicester, England (R.H., C.E.B.); Novartis, Basel, Switzerland (R.K.); and INSIGNEO Institute of In-silico Medicine, Sheffield, England (A.J.S., J.M.W.)
| | - Wim Vos
- From the Academic Units of Academic Radiology (B.A.T., A.J.S., F.C.H., H.M., J.C.K., J.P.R., J.M.W.) and Clinical Oncology (B.A.T., R.H.I.), University of Sheffield, C Floor, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, England; Fluidda, Kontich, Belgium (C.V.H., J.D.B., W.V.); Institute for Lung Health, University of Leicester, Leicester, England (R.H., C.E.B.); Novartis, Basel, Switzerland (R.K.); and INSIGNEO Institute of In-silico Medicine, Sheffield, England (A.J.S., J.M.W.)
| | - Jim M Wild
- From the Academic Units of Academic Radiology (B.A.T., A.J.S., F.C.H., H.M., J.C.K., J.P.R., J.M.W.) and Clinical Oncology (B.A.T., R.H.I.), University of Sheffield, C Floor, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, England; Fluidda, Kontich, Belgium (C.V.H., J.D.B., W.V.); Institute for Lung Health, University of Leicester, Leicester, England (R.H., C.E.B.); Novartis, Basel, Switzerland (R.K.); and INSIGNEO Institute of In-silico Medicine, Sheffield, England (A.J.S., J.M.W.)
| |
Collapse
|